Editorial · 2025 · Open access
In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?
Cureus, 17(5), e84007 · Published 13 May 2025 · DOI 10.7759/cureus.84007
In brief
“In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?” is an 2025 editorial by Shaheen Emmanuel Lakhan, published in Cureus. OpenAlex counts 6 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Cureus.
- Citations
- 6
- Most cited in
- 2026 (5)
- References
- 14
- Authors
- 1
Abstract
Recent advances in computational biology, artificial intelligence (AI), and regulatory science are rapidly displacing the traditional reliance on animal and early-phase human trials in drug development. In April 2025, the U.S. Food and Drug Administration announced a landmark decision to phase out mandatory animal testing for many drug types, signaling a paradigm shift toward in silico methodologies. This editorial explores how computer-based models, especially digital twins, are emerging as the fourth pillar of biomedical science, capable of simulating complex human systems with remarkable accuracy. Drawing on real-world examples from oncology, neurology, and regulatory submissions, the editorial argues that in silico tools are no longer ancillary but central to modern research. These technologies enable rapid, ethical, and cost-effective drug discovery while offering personalized therapeutic insights. As machine learning, multi-omics integration, and predictive simulations mature, their regulatory credibility grows, particularly in initiatives such as model-informed drug development and digital therapeutics. The editorial concludes by urging the adoption of standardized frameworks, explainable AI, and infrastructure investment to ensure in silico research fulfills its transformative potential. Within a decade, failure to employ these methods may no longer be merely outdated, it may be indefensible.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lakhan, S. E. (2025). In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials? Cureus, 17(5), e84007. https://doi.org/10.7759/cureus.84007
MLA 9
Lakhan, Shaheen Emmanuel. “In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?” Cureus, vol. 17, no. 5, 2025, p. e84007. https://doi.org/10.7759/cureus.84007.
Chicago
Lakhan, Shaheen Emmanuel. 2025. “In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?” Cureus 17 (5): e84007. https://doi.org/10.7759/cureus.84007.
Harvard
Lakhan, S. E. (2025) ‘In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?’, Cureus, 17(5), p. e84007. doi:10.7759/cureus.84007.
IEEE
S. E. Lakhan, “In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?,” Cureus, vol. 17, no. 5, p. e84007, 2025, doi: 10.7759/cureus.84007.
BibTeX
@article{lakhan2025silico,
title = {{In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials?}},
author = {Lakhan, Shaheen Emmanuel},
journal = {Cureus},
year = {2025},
volume = {17},
number = {5},
pages = {e84007},
doi = {10.7759/cureus.84007},
url = {https://doi.org/10.7759/cureus.84007}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- digital twin
- FDA regulation
- model-informed drug development
- digital therapeutics
- machine learning
- multi-omics integration
- predictive simulation
- explainable AI
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Lakhan, S. E. (2025). In Silico Research Is Rewriting the Rules of Drug Development: Is It the End of Human Trials? Cureus, 17(5), e84007. https://doi.org/10.7759/cureus.84007
How many times has this paper been cited?
6 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Cureus.
Who wrote this paper?
Shaheen Emmanuel Lakhan.
What is the DOI of this paper?
10.7759/cureus.84007. The permanent link is https://doi.org/10.7759/cureus.84007.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.